157 related articles for article (PubMed ID: 9264362)
1. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system.
Bresalier RS; Yan PS; Byrd JC; Lotan R; Raz A
Cancer; 1997 Aug; 80(4):776-87. PubMed ID: 9264362
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors.
Kitange G; Kishikawa M; Nakayama T; Naito S; Iseki M; Shibata S
Mod Pathol; 1999 Jun; 12(6):618-26. PubMed ID: 10392639
[TBL] [Abstract][Full Text] [Related]
3. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Yamamoto M; Ikeda K; Ohshima K; Tsugu H; Kimura H; Tomonaga M
Cancer Res; 1997 Jul; 57(13):2799-805. PubMed ID: 9205092
[TBL] [Abstract][Full Text] [Related]
5. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity and alterations in telomere length in human brain tumors.
Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study.
Rodriguez FJ; Scheithauer BW; Roncaroli F; Silva AI; Kovacs K; Brat DJ; Jin L
Am J Surg Pathol; 2008 Sep; 32(9):1344-52. PubMed ID: 18670355
[TBL] [Abstract][Full Text] [Related]
8. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
10. The glucose transporter and blood-brain barrier of human brain tumors.
Guerin C; Laterra J; Hruban RH; Brem H; Drewes LR; Goldstein GW
Ann Neurol; 1990 Dec; 28(6):758-65. PubMed ID: 2178329
[TBL] [Abstract][Full Text] [Related]
11. Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas.
Gunal A; Onguru O; Safali M; Beyzadeoglu M
Neuropathology; 2008 Aug; 28(4):382-6. PubMed ID: 18298442
[TBL] [Abstract][Full Text] [Related]
12. Fascin expression in 90 patients with glioblastoma multiforme.
Roma AA; Prayson RA
Ann Diagn Pathol; 2005 Dec; 9(6):307-11. PubMed ID: 16308158
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
14. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Erdamar S; Bagci P; Oz B; Dirican A
J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of galectin-3 expression by sarcomas, pseudosarcomatous and benign lesions of the soft tissues. Preliminary results of an immunohistochemical study.
Bigotti G; Coli A; Del Vecchio M; Massi G
J Exp Clin Cancer Res; 2003 Jun; 22(2):255-64. PubMed ID: 12866576
[TBL] [Abstract][Full Text] [Related]
16. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system.
Sasaki T; Lopes MB; Hankins GR; Helm GA
Acta Neuropathol; 2002 Jul; 104(1):105-9. PubMed ID: 12070671
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of mortalin expression in human brain tumors.
Takano S; Wadhwa R; Yoshii Y; Nose T; Kaul SC; Mitsui Y
Exp Cell Res; 1997 Nov; 237(1):38-45. PubMed ID: 9417864
[TBL] [Abstract][Full Text] [Related]
18. Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation.
Plzák J; Smetana K; Hrdlicková E; Kodet R; Holíková Z; Liu FT; Dvoránkova B; Kaltner H; Betka J; Gabius HJ
Int J Oncol; 2001 Jul; 19(1):59-64. PubMed ID: 11408923
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3: a useful biomarker for differential diagnosis of brain tumors.
Park SH; Min HS; Kim B; Myung J; Paek SH
Neuropathology; 2008 Oct; 28(5):497-506. PubMed ID: 18384511
[TBL] [Abstract][Full Text] [Related]
20. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
